Satralizumab for Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD)

Satralizumab is being developed as a treatment for people with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). MOGAD is a rare autoimmune condition in which the body’s immune system attacks the protective covering of nerves in the brain, spinal cord, and optic nerves. This damage interferes with how nerve signals travel and can cause symptoms such as blurred or painful vision, vision loss, weakness, numbness, and, in some cases, seizures. Many people with MOGAD experience repeated attacks over time, known as relapses, which can lead to lasting disability. There are currently no licensed treatments specifically approved to prevent relapses in MOGAD, and care often relies on medicines that broadly suppress the immune system. This creates a clear unmet need for targeted and proven treatment options.